spacer
home > ebr > winter 2018 > cell-ebration
PUBLICATIONS
European Biopharmaceutical Review

Cell-ebration

Ever since scientists learned how to culture cells and tissue outside a living organism (in vitro) the method has served as an excellent, highly controlled experimental platform that has helped them understand the basics of cellular physiology: how cells function and respond to different stimuli. The era of ‘cell culturing’ started in the late 19th century with the development of the ‘Ringer solution’ – named after the British physiologist Sydney Ringer – and was further established by a number of pioneering publications by Ross Granville Harrison in the early 20th century (1-4).

With the discovery of how cells in culture can be multiplied and with the establishment of the first human-derived cell line (the ‘HeLa’ cells), a new avenue of research opened up for cell biologists, together with the foundation of work leading to fundamental knowledge about cellular behaviour.

However, although in vitro systems have been important during the last hundred years, there is an acceptance and mass of evidence that traditional two-dimensional (2D) in vitro systems – ie cells grown at the bottom of a glass flask – poorly reflect the complexity of the in vivo process. In the in vitro environment, tissue-specific architecture, mechanical and biochemical cues and cell-cell communications are absent (see Table 1), resulting in transitional issues within pharmaceutical research when going from in vitro-based models to animal models, ie ‘from bench to bedside’ (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Fredrik Johansson has an MSc in biophysics and a PhD in zoological cell biology. His research is focused on physical cues in interfaces between cells/tissue and artificial nanostructures. Frederik’s main body of publications describe how neurons in general and their cell extensions, in particular the axons, are affected by small structures. The nanostructures he has worked with are nanoimprinted polymer patterns, porous silicon and electrospun fibers, among others. Research into electrospinning also led to the formation of an electrospinning company Cellevate AB, of which Frederik is one of the cofounders. He is now an Associate Professor at Lund University, Sweden.

Maximilian Ottosson is one of the co-founders and the current Chief Executive Officer of Cellevate, a Swedish company working with the production and commercialisation of nanofibrous materials for life sciences applications such as tissue engineering and 3D cell culture. The company has so far successfully launched a product line for 3D cell culture based on fiber materials. Maximilian has an MSc in engineering, engineering nanoscience, with a specialisation in nano-biomedicine and biophysics from Lund University, Sweden.

spacer
Professor Fredrik Johansson
spacer
spacer
spacer
Maximilian Ottosson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

c-LEcta signs Europe sales and distribution agreement with VWR for c-LEcta’s DENARASE®

• DENARASE® is now available through VWR’s sales channels in Europe • VWR, part of Avantor, is a leading global provider of product and service solutions to laboratory and production customers • Cooperation harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

Outsourcing Clinical Trials Nordics 2018

30-31 October 2018, Copenhagen, Denmark

Following on from the success of the 2017 Outsourcing in Clinical Trials Nordics conference, Arena International is pleased to announce that the event will return for its 6th year in 2018. The 2018 event welcomes biopharmaceutical and medical device companies from across the Nordic region to share knowledge and challenges of outsourcing and clinical operations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement